Your main tasks include inhalation formulation and manufacturing process development for our proprietary DPI device platform. You work as a CMC team member in development phase inhalation projects. Your main responsibility is to design formulations, plan and run studies exploring their feasibility and confirming their appropriateness for the intended use. You will review results, summarize and make conclusions of the studies, and document the work for registration purposes. You will collaborate with internal and external stakeholders working closely together in multi-disciplinary teams, and guide the work of Research Assistants in the formulation laboratory. You will also develop inhalation product development activities and follow international development.
Description of function
Inhalation Product Development is part of Global Pharmaceutical Research in R&D. The team is responsible for CMC development of inhalation products and related analytical activities. Our team consists of formulation and analytical scientists as well as research assistants.
M.Sc. degree in pharmacy is required, along with practical experience in pharmaceutical product development of inhalation products as well as production processes. To succeed you need to understand the theoretical background of inhalation development and you are also capable of working in the laboratory. You propose practical solutions to address identified problems and you actively participate and contribute to team processes. You are a creative thinker with the ability to devise new ideas and solve problems. Fluent oral and written skills in English are essential.
We offer fascinating challenges in inhalation development among highly motivated and capable colleagues. We actively develop our operations and fight diseases by innovative treatments to improve quality of lives.
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,085 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki.